SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending as the community debates its ongoing turnaround efforts, with investors closely watching management's latest acquisition plans and expansion into a unified home services platform. While some retail traders are analyzing the stock for potential momentum, others remain skeptical about its long-term viability and the dilution risks associated with its strategic shifts.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing a strong rally following a solid Q1 earnings beat and raised full-year guidance, with investors cheering better-than-expected medical loss ratios and a robust share buyback program. Community sentiment has shifted to aggressive optimism as traders discuss a potential breakout toward $400, viewing the move as a long-awaited recovery for the sector giant.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is currently under intense scrutiny as a divide forms between institutional investors and retail traders regarding its long-term viability and certification milestones. Community discussion is heavily split, with many highlighting recent NYC flight demonstrations as a proof-of-concept while others criticize the high cash burn and recent downward price trends as a sign of institutional manipulation and lack of commercial readiness.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending following a record-breaking earnings report that highlighted strong user growth and improved profitability, though the stock experienced a volatile sell-off as investors reacted to slightly light subscriber guidance. The community remains divided, with many debating whether the pullback represents a buying opportunity for a long-term compounder or a sign of slowing momentum in a maturing market.

One & One Green Technologies, Inc. engages in the recycling, production, and trading of recycled scrap metals. Its products include copper alloy ingot, recycled aluminum, recycled tin, recycled zinc, recycled iron, and plastic beads. The company was founded on April 17, 2024 and is headquartered in Bulacan, Philippines.

One and one Green Technologies. Inc - Ordinary Shares - Class A

One and One Green Technologies Inc

One and One Green Technologies is drawing significant investor interest following a volatile IPO debut, with the community closely tracking its low-float dynamics and insider-heavy ownership structure. Traders are debating the company's long-term sustainability in the Philippine e-waste recycling sector versus its current status as a speculative momentum play.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is capturing intense investor interest as the stock experiences high-volume, parabolic moves driven by speculation surrounding a potential buyout and excitement over its late-stage biotech pipeline. The community is actively discussing the companys strong institutional backing and tight effective float, with many debating the impact of upcoming conference presentations and the possibility of a strategic partnership or acquisition.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is trending as investors weigh its recent $750 million acquisition of DustPhotonics, a move seen as a strategic pivot to bolster its silicon photonics capabilities alongside its established copper-based connectivity portfolio. While the community is actively debating the long-term competition between copper and optical technologies in AI infrastructure, bullish sentiment remains centered on the company's strong revenue growth and role as a key supplier for hyperscale data center buildouts.

Rambus, Inc. engages in the provision of cutting-edge semiconductor and Internet Protocol products, spanning memory and interfaces to security, smart sensors and lighting. Its products include Memory Interface Chips, Interface IP, and Security IP. The company was founded by P. Michael Farmwald and Mark A. Horowitz in March 1990 and is headquartered in Sunnyvale, CA.

Rambus Inc.

Rambus is experiencing significant volatility following a post-earnings sell-off that wiped out gains from a recent rally, with investors debating whether this is a structural shift or a temporary shakeout. While the company faces pressure from supply chain issues and softer-than-expected guidance, the community remains divided between those capitalizing on the dip as a long-term AI-driven play and those concerned about weakening momentum relative to the broader semiconductor sector.

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Erasca Inc

Erasca (ERAS) is facing intense volatility and a sharp sell-off following the disclosure of a patient death in its ERAS-0015 Phase 1 trial, which some investors fear could trigger an FDA clinical hold. The community remains heavily divided, with critics alleging the company obfuscated safety risks in an 8-K filing while pushing counterfeit-labeled data, while proponents argue the reaction is an overblown opportunity to buy the dip in a company with a strong cash position and best-in-class potential.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola is trending as investors weigh strong Q1 earnings, where the company beat analyst expectations for both revenue and EPS, against a broader market environment of rising geopolitical uncertainty. Community discussion is heavily focused on the stock's defensive appeal and reliable dividend growth, though some voices are debating the impact of premium pricing on long-term volume growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Polyrizon Signs MOU To Acquire Up To 20% Stake In Colugo; Stock Plunges In Pre-market

(RTTNews) - Polyrizon Ltd. (PLRZ), an Israeli pre-clinical stage biotechnology company, on Tuesday, signed a non-binding memorandum of understanding to acquire up to a 20% stake in a developer of...

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX, Drug-Free Allergy Blocker

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX, Drug-Free Allergy Blocker Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX, Drug-Free Allergy Blocker PR Newswire...

<ul class="summary-bullets"><li>Arrow Aviation provides private flights to the public sector, with specialized operations such as air ambulances.</li><li>The deal includes transferring a Hawker 800 aircraft valued at $3.5 million to Arrow Aviation.</li><li>The MoU also grants options to acquire the remaining 49% after two years, Polyrizon said.</li></ul>Shares of Polyrizon (PLRZ) gained 6% in premarket trading on Tuesday after the company announced that it recently signed a memorandum of understanding to acquire a 51% stake in global private aviation firm Arrow Aviation through a cash investment of NIS 18 million ($5.8 million).“We believe that this strategic move, upon completion, represents an exciting diversification opportunity for Polyrizon, allowing us to leverage our strong financial position to enter the dynamic private aviation market, a market set to grow to $41.38 billion by 2030, through a potential acquisition of a high-growth, high-potential company,” said Tomer Izraeli, CEO of Polyrizon.<h2 class="st-heading-2">Deal Rationale</h2>Arrow Aviation provides private flights to the public sector, with specialized operations including air ambulances, medical evacuations, rescue missions, special-needs transport, medical tourism, and cargo services, including the transport of sensitive and hazardous materials under special licenses.The company last reported annual unaudited revenues of around $19 million and adjusted earnings before interest, tax, depreciation and amortization (EBITDA) of around $3 million.The deal includes transferring a Hawker 800 aircraft valued at $3.5 million to Arrow Aviation in exchange for a convertible note issued by Polyrizon.&nbsp;Arrow Aviation shareholders will also forgive outstanding debts for convertible notes, allowing the company to operate debt-free after closing. The MoU grants options to acquire the remaining 49% after two years, with a definitive agreement expected within 30 days, subject to due diligence.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday gains, retail sentiment on Stocktwits turned 'neutral' from 'bullish' a day earlier.One user noted the increasing volumes traded and the company's market cap.<stembedurl>https://stocktwits.com/raulaa/message/644568154</stembedurl><a href="https://stocktwits.com/symbol/PLRZ">PLRZ shares</a> have gained more than 66% so far this year.$1 = NIS 3.1For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

PLRZ Stock Jumps 6% In Pre-Market – Why Is This Biotech Firm Diversifying Into Aviation Business?

The company announced that it recently signed an MoU to acquire a 51% stake in private aviation firm Arrow Aviation for around $5.8 million.

Equity

Polyrizon Partners With Clearmind To Advance Intranasal MEAI For CNS Disorders

(RTTNews) - Clearmind Medicine (CMND) announced that it has entered into a development agreement with Polyrizon to create a proprietary intranasal formulation of MEAI, a non-hallucinogenic...

Small Cap Stocks To Keep An Eye On - December 4th

SMX (Security Matters) Public, Spring Valley Acquisition, Direxion Daily META Bull 2X Shares, Polyrizon, and Direxion Daily TSLA Bear 1X Shares are the five Small Cap stocks to watch today, according...

Top Biotech Stocks To Consider - December 4th

Danaher, Polyrizon, Vertex Pharmaceuticals, Medpace, Abivax, Capricor Therapeutics, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

Polyrizon Stock Skyrockets After New Data Shows Naloxone Gel Outperforms Marketed Spray

Polyrizon stock is up on new data showing its naloxone hydrogel formulation has stronger and longer-lasting mucosal retention.read more...

What Sparked Polyrizon's (PLRZ) 140% After-Hours Stock Surge?

Polyrizon surged in nearly 140% after-hours trading following preclinical data showing its naloxone hydrogel outperforms a marketed spray and a key manufacturing milestone.read more...

Polyrizon Hits Key Breakthrough That Brings Its Nasal Spray Closer To 2026 Trials

Polyrizon jumps over 100%. The company completes major manufacturing milestone for its proprietary nasal-spray product platform.read more...

<ul class="summary-bullets"><li>The expanded production ensures that the PL-14 spray can be reliably manufactured at higher volumes.</li><li>Following the update, Polyrizon’s stock traded over 82% higher in Tuesday’s premarket.</li><li>The upscaled process is designed to provide clinical trial material (CTM) for studies scheduled to begin in 2026.</li></ul>Polyrizon (PLRZ) announced on Tuesday a major manufacturing milestone for its proprietary nasal spray platform, bringing the company closer to supporting upcoming clinical trials and potential commercial availability.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/PLRZ">Polyrizon’s stock</a> traded over 73% higher in Tuesday’s premarket. On Stocktwits, retail sentiment for the stock improved to ‘extremely bullish’ from ‘bullish’ territory, amid ‘high’ message volumes.&nbsp;<h2 class="st-heading-2">Milestone Achievement</h2>Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation.&nbsp;The expanded production ensures that the PL-14 spray can be reliably manufactured at higher volumes while maintaining the quality standards necessary for clinical trials.<blockquote>"The process validated our manufacturing strategy.”&nbsp;-Tomer Izraeli, CEO, Polyrizon&nbsp;</blockquote>“With this batch in hand, we are energized and prepared to advance into next batches towards clinical trial material manufacturing, which we believe brings us one step closer to addressing the unmet needs in the nasal spray market."<h2 class="st-heading-2">Preparing For Clinical Trials</h2>The upscaled process is designed to provide clinical trial material (CTM) for studies scheduled to begin in 2026. Polyrizon’s manufacturing procedures align with theU.S. and European regulatory requirements.The PL-14 nasal spray is engineered to create a fast-acting, moisturizing barrier in the nasal cavity, helping trap, isolate, and neutralize airborne allergens before they contact mucosal tissues. Developed using Polyrizon’s proprietary Capture &amp; Contain (C&amp;C) bio-adhesive technology, the spray offers extended, non-pharmacological protection for people exposed to high levels of environmental allergens.&nbsp;PLRZ stock has lost over 99% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mongodb-stock-rises-premarket-as-analysts-increase-price-targets/cLIajIsRE0t">MongoDB’s Atlas Engine Drives A Wave Of Price Target Hikes – Stock Pops In Premarket Trade</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Polyrizon Stock Soar Pre-Market Today? 

Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation. 

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

PLRZ
Polyrizon Ltd. Ordinary Shares

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PLRZ News

PLRZPolyrizon Ltd. Ordinary Shares